These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 20194843

  • 21. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C, Sattler M.
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [Abstract] [Full Text] [Related]

  • 22. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A, Prasad K.
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [Abstract] [Full Text] [Related]

  • 23. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M.
    Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
    [Abstract] [Full Text] [Related]

  • 24. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E, Cortes J, Kantarjian H.
    Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
    [Abstract] [Full Text] [Related]

  • 25. [Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].
    Nasr R, Bazarbachi A.
    Pathol Biol (Paris); 2012 Aug; 60(4):239-45. PubMed ID: 22743097
    [Abstract] [Full Text] [Related]

  • 26. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Quintás-Cardama A, Kantarjian H, Cortes J.
    N Engl J Med; 2007 Oct 11; 357(15):1557; author reply 1557-8. PubMed ID: 17933034
    [No Abstract] [Full Text] [Related]

  • 27. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA, Junaid A, Siddiqui NS, Mukhtar K, Siddiqui S.
    J Coll Physicians Surg Pak; 2008 Mar 11; 18(3):176-8. PubMed ID: 18460249
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
    Oyekunle AA, Castagnetti F, Gugliotta G, Soverini S, Baccarani M, Rosti G.
    Leuk Res; 2011 Jul 11; 35(7):e118-20. PubMed ID: 21489624
    [No Abstract] [Full Text] [Related]

  • 33. Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia.
    Koldehoff M, Elmaagacli AH.
    Methods Mol Biol; 2009 Jul 11; 487():451-66. PubMed ID: 19301661
    [Abstract] [Full Text] [Related]

  • 34. Imatinib resistance and blast transformation of chronic myeloid leukemia associated with a novel tri-nucleotide insertion mutation of BCR-ABL kinase domain at position K294.
    Nadarajan VS, Ang CH, Syed-Sultan MK, Bee PC.
    Ann Hematol; 2012 Jan 11; 91(1):125-7. PubMed ID: 21442193
    [No Abstract] [Full Text] [Related]

  • 35. Imatinib and regression of type 2 diabetes.
    Veneri D, Franchini M, Bonora E.
    N Engl J Med; 2005 Mar 10; 352(10):1049-50. PubMed ID: 15758023
    [No Abstract] [Full Text] [Related]

  • 36. Chronic myelocytic leukemia--Part II: Approaches to and molecular monitoring of therapy.
    Randolph TR.
    Clin Lab Sci; 2005 Mar 10; 18(1):49-56. PubMed ID: 15747786
    [Abstract] [Full Text] [Related]

  • 37. Imatinib and chronic-phase leukemias.
    Boros LG, Lee WN, Cascante M.
    N Engl J Med; 2002 Jul 04; 347(1):67-8. PubMed ID: 12097546
    [No Abstract] [Full Text] [Related]

  • 38. An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate.
    Leguay T, Desplat V, Lagarde V, Marit G, Reiffers J, Mahon FX.
    Leukemia; 2005 Sep 04; 19(9):1671-3. PubMed ID: 15973458
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Chronic myeloid leukemia: how can minimal cytogenetic response after 3 months of treatment be classified according to the new European LeukemiaNet recommendations?
    Jiménez-Velasco A, Barrios M, Alcalá M, Heiniger AI.
    J Clin Oncol; 2010 Jun 20; 28(18):e310; author reply e311. PubMed ID: 20479423
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.